Volume 23, Issue 6 p. 379-385
Research Article

Genistein treatment protects mice from ionizing radiation injury

Michael R. Landauer

Corresponding Author

Michael R. Landauer

Radiation Casualty Management Team, Armed Forces Radiobiology Research Institute, 8901 Wisconsin Avenue, Bethesda, MD 20889-5603, USA

AFRRI, Bldg. 42, 8901 Wisconsin Ave, Bethesda, MD, 20889-5603, USA.Search for more papers by this author
Venkataraman Srinivasan

Venkataraman Srinivasan

Radiation Casualty Management Team, Armed Forces Radiobiology Research Institute, 8901 Wisconsin Avenue, Bethesda, MD 20889-5603, USA

Search for more papers by this author
Thomas M. Seed

Thomas M. Seed

Radiation Casualty Management Team, Armed Forces Radiobiology Research Institute, 8901 Wisconsin Avenue, Bethesda, MD 20889-5603, USA

Search for more papers by this author
First published: 17 November 2003
Citations: 113

This article is a US Government work, and is in the public domain in the USA.

Abstract

The radioprotective and behavioral effects of an acute administration of the isoflavone genistein (4′,5,7-trihydroxyflavone) were investigated in adult CD2F1 male mice. Mice were administered a single subcutaneous (s.c.) dose of genistein either 24 h or 1 h before a lethal dose of gamma radiation (9.5-Gy of cobalt-60 at 0.6 Gy min−1). Mice received saline, PEG-400 vehicle or genistein at 3.125, 6.25, 12.5, 25, 50, 100, 200, or 400 mg kg−1 body weight. For mice treated 24 h before irradiation there was a significant increase in 30-day survival for animals receiving genistein doses of 25 to 400 mg kg−1 (p < 0.001). In contrast, the 30-day survival rates of mice treated with genistein 1 h before irradiation were not significantly different from those of the vehicle control group. Additionally, the acute toxicity of genistein was evaluated in non-irradiated male mice administered a single s.c. injection of saline, vehicle, or genistein at 100, 200 or 400 mg kg−1. At these genistein doses there were no adverse effects, compared with controls, on locomotor activity, grip strength, motor coordination, body weight, testes weight, or histopathology. These results demonstrate that a single s.c. administration of the flavonoid genistein at non-toxic doses provides protection against acute radiation injury. Published in 2003 by John Wiley & Sons, Ltd.